NAHL Group Reports 289% Surge in Pre-Tax Profit and Decade-Low Debt in H1 2025

Critical Care: expert witness strength offsets case management softness

Critical Care delivered steady growth: revenue up 2% to £8.2m, underlying operating profit up 1% to £2.6m, and a robust margin of 31.5% (H1 2024: 31.8%). Cash from operations rose to £2.3m (H1 2024: £2.1m). Recurring revenue represented around 43% of the division.

Expert witness services were the standout. Revenue rose 11%; reports issued increased 13% to 719 as the associate network expanded to 226 (from 196 at the start of the year). Instruction levels were broadly stable.

Case management was more challenging. Revenue fell 9%; Initial Needs Assessments (INAs – the first formal assessment that often leads to ongoing case management) dropped to 210 from 261. Ongoing clients were 1,157 (H1 2024: 1,388), reflecting fewer insurer instructions and higher discharge rates. To tackle this, management is strengthening account management, expanding the associate pool (now 142) and improving triage processes. Two growth levers are gaining traction: Bush & Co. Kids, a child-focused proposition launched late last year, and Bush & Co. Care Solutions, which grew revenue 26% to £0.4m with an increase to 34 live care packages.

The previously announced sale process for Bush & Co. ended without a transaction. That’s not ideal for a quick de-gearing moment, but it removes uncertainty and lets the team focus on execution. A new Divisional Finance Director joined in September to support improvements and growth.

Balance sheet and cash: interest costs down, flexibility up

Free cash flow doubled to £1.5m and operating cash conversion was 102%, reflecting improved profitability and disciplined working capital. Interest expense fell to £0.3m from £0.5m as NAHL repaid £1.8m of its revolving credit facility in the period. Net debt dropped to £5.6m at 30 June 2025 – down 22% since December and 38% year on year – and nudged lower again to £5.5m by 31 August. The £12.0m facility runs to 31 December 2026.

EPS rose to 3.0p, from 0.7p, on the back of the profit recovery. Dividends remain paused – the interim dividend is nil – which is sensible while the group continues to invest in NAL and reduce debt.

Outlook: guidance intact and early Q3 trading supportive

The Board expects to deliver a full-year outturn in line with market expectations. Early H2 signs are encouraging. In July and August, CLS generated 2,452 new enquiries, a monthly average 12% higher than H1 and at a lower acquisition cost. NAL collected £1.5m from settled claims versus £1.4m in the same period last year. In Critical Care, 230 expert witness reports were issued (239 last year) and 81 INAs (88 last year) – broadly steady on expert work and still softer on case management.

Importantly, since the Bush & Co. sale process concluded, the Board has been exploring alternative options to accelerate shareholder value. No specifics yet – “further work is required” – but expect updates in due course.

My take: quality of earnings improving, but a few watch-outs

• Positives: profit before tax up 289% to £1.9m, strong free cash flow and a 10-year low in net debt. NAL is delivering higher-value settlements and better cash, which is the right kind of improvement. Critical Care maintains a 31.5% margin and healthy expert witness demand. Interest costs are falling, extending financial headroom.
• Execution gains: marketing discipline cut spend by £1.3m while lifting the share of enquiries into NAL to 34%. That should support future margins as more value is captured in-house.
• Negatives: enquiry volumes are down year on year, reflecting a deliberate reset, and the panel market remains structurally smaller. NAL’s claims in progress fell to 7,530; embedded value is solid, but NAL will “require higher levels of investment” to reach its medium-term potential. In Critical Care, case management remains tough with fewer insurer instructions and higher discharges.

Overall, the quality of earnings looks better than a year ago – fewer low-return enquiries, more value per settled case, and strong cash discipline. If the second half sustains the enquiry momentum and Critical Care stabilises case management, NAHL has a clear runway to keep reducing debt and growing EPS.

What to watch next

• Flow and quality of new enquiries, and the proportion directed to NAL.
• Cash collected from settlements – the real-world confirmation of value.
• Case management instruction trends and discharge rates in Critical Care.
• Any Board update on “alternative options” to accelerate shareholder value.
• Further deleveraging versus the £12.0m facility due in 2026.

Useful links

• NAHL Group
• National Accident Helpline
• National Accident Law
• Bush & Co.